Marvel Biosciences Corp (TSE:MRVL)
:MRVL
Want to see TSE:MRVL full AI Analyst Report?
MRVL Stock Chart & Stats
C$0.14
-C$0.01(-6.45%)
At close: 4:00 PM EST
C$0.14
-C$0.01(-6.45%)
Day’s Range― - ―
52-Week RangeC$0.08 - C$0.40
Previous CloseN/A
Volume5.00K
Average Volume (3M)89.38K
Market Cap
C$10.40M
Enterprise ValueC$12.44M
Total Cash (Recent Filing)C$274.17K
Total Debt (Recent Filing)C$2.31M
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Jun 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding63,028,290
10 Day Avg. Volume75,294
30 Day Avg. Volume89,378
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)-2.07
Price to Sales (P/S)0.00
P/FCF Ratio-7.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Cash Burn TrendA multi-year improvement in cash burn is a durable operational positive: it lengthens runway per financing round, reduces near-term dilution pressure and gives management more time to progress R&D milestones that can materially change the company's financing and commercial prospects over the next several months.
Narrowing Net LossesA clear trend of smaller annual losses signals improving cost control or efficiencies in development programs. Persisting this trajectory over 2–6 months supports a more sustainable burn rate, improving the company's ability to fund critical milestones without immediate large financings.
Lean Operating StructureA very small headcount is a durable structural advantage for an early-stage biotech: lower fixed overheads reduce cash consumption, allow focused allocation of capital to core R&D, and extend runway per dollar raised—helpful while the company remains pre-revenue.
Bears Say
Pre-revenue With Negative Gross ProfitBeing pre-revenue with negative gross profit is a fundamental constraint: the company lacks operating cash inflows and depends on external financing to sustain R&D and operations. This structural state heightens execution risk and means commercial validation remains a material milestone to achieve.
Negative Shareholder Equity And Meaningful DebtMaterial negative equity combined with non-trivial debt reduces financial flexibility and increases refinancing and covenant risk. Over 2–6 months this raises the probability of dilutive financings or debt restructuring, constraining strategic optionality and long-term capital allocation.
Persistent Negative Operating Cash FlowSustained negative operating and free cash flow is a durable headwind: ongoing funding needs impose recurring financing risk, can force dilution or limit R&D spending, and make it harder to fund late-stage development or commercialization without clear near-term financing sources.
Marvel Biosciences Corp News
MRVL FAQ
What was Marvel Biosciences Corp’s price range in the past 12 months?
Marvel Biosciences Corp lowest stock price was C$0.07 and its highest was C$0.40 in the past 12 months.
What is Marvel Biosciences Corp’s market cap?
Marvel Biosciences Corp’s market cap is C$10.40M.
When is Marvel Biosciences Corp’s upcoming earnings report date?
Marvel Biosciences Corp’s upcoming earnings report date is Jun 23, 2026 which is in 49 days.
How were Marvel Biosciences Corp’s earnings last quarter?
Marvel Biosciences Corp released its earnings results on Mar 31, 2026. The company reported -C$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.005.
Is Marvel Biosciences Corp overvalued?
According to Wall Street analysts Marvel Biosciences Corp’s price is currently Overvalued.
Does Marvel Biosciences Corp pay dividends?
Marvel Biosciences Corp does not currently pay dividends.
What is Marvel Biosciences Corp’s EPS estimate?
Marvel Biosciences Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marvel Biosciences Corp have?
Marvel Biosciences Corp has 63,028,290 shares outstanding.
What happened to Marvel Biosciences Corp’s price movement after its last earnings report?
Marvel Biosciences Corp reported an EPS of -C$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.941%.
Which hedge fund is a major shareholder of Marvel Biosciences Corp?
Currently, no hedge funds are holding shares in TSE:MRVL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marvel Biosciences Corp
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
Technical Analysis
BetterLife Pharma
―
―
Entheon Biomedical
―
Bright Minds Biosciences
―
MYND Life Sciences
―
Options Prices
Currently, No data available
---